To access the localized content, select the website associated with the Division of your interest:

Health & Safety

    Healthcare & Life Sciences

      Energy & Mobility

        Investor Relations

        Press Releases

        Press releases

        1. 2023 Calendar Of Corporate Financial Events
        2. GVS loses PMI (SME) status
        3. GVS_ Disclosure of total amount of voting rights

        1. Agreement to amend and adjust the financial covenant (leverage ratio) and commitment of the Shareholder to provide a subordinated shareholder loan
        2. GVS Board of Directors approved the consolidated results as at 30 September 2022
          Price Sensitive
        3. Marco Pacini is the new Group CFO of GVS
          Price Sensitive
        4. Notice: Publication of Documentation
        5. The GVS BoD approved the consolidated results as at 30 June 2022
          Price Sensitive
        6. Haemotronic Acquisition closing
        7. Notice of pubblication
        8. GVS Acquisition of 100% of the Italian Group Haemotronic - Integration of the Press Release
        9. GVS acquires 100% of the Italian Group Haemotronic, leader in the production of components in the medical and pharmaceutical industries for 212 million euro
          Price Sensitive
        10. GVS Haemotronic Acquisition Analyst Presentation
        11. GVS Haemotronic's Acquisition - AUDIO
        12. The GVS BoD approved the consolidated results as at 31 March 2022
        13. GVS Shareholders' Meeting approves 2021 Financial Statements
        14. Notice on total amount of voting rights
        15. Notice pubblication of documentation
        16. The Board of Directors convenes the shareholders' meeting for Thursday 28 April 2022
        17. The GVS Board of Directors approved the 2021 consolidated results and the draft financial statements as at 31 December 2021
          Price Sensitive
        18. Acquisition of Shanghai Transfusion Technology Co. Ltd. completed a strategic opportunity for GVS to fully enter the Chinese healthcare market
        19. Conclusion of the first part of the treasury shares purchase program
          Price Sensitive
        20. Share buyback information
          Price Sensitive
        21. Share buyback information
        22. 2022 Corporate Events Calendar
        23. Share buyback information

        1. 3F Buyback Dicember 2021
        2. Share buyback information
        3. Share buyback information
        4. GVS Acquires 100% of the Shanghai Transfusion Technology Co., LTD.
          Price Sensitive
        5. Share buyback information
        6. Share buyback information
        7. 3F Buyback November 2021
        8. Share buyback information
        9. Share buyback information
        10. Share buyback information
        11. Notice of Publication of Documents
        12. GVS Approves consolidated results to 30 September 2021
          Price Sensitive
        13. Share buyback information
        14. 3F Buyback October 2021
        15. Share buyback information
        16. Share buyback information
        17. Share buyback information
        18. GVS Launches treasury share buyback programme
          Price Sensitive
        19. GVS Approves consolidated results to 30 June 2021 revenues up 29.7%, EBITDA margin at 37.9%
          Price Sensitive
        20. GVS Acquires 100% of the RPB Group, an American player specialised in the design and production of respiratory protection devices, and completes its product range in the world of professional masks
          Price Sensitive
        21. GVS Approves consolidated results as at 31 March 2021
          Price Sensitive
        22. The GVS BOD approves the 2020 financial statement: revenues up 60%, strong growth in Group profitability and solid increase in all key economic and financial indicators
          Price Sensitive
        23. 2021 Corporate Events Calendar
          Price Sensitive

        1. GVS Approves the consolidated results at 30 September 2020 revenue up 49.6% and marked growth of the Group’s profit margin
          Price Sensitive
        2. The BOD of GVS approves the first half 2020 results revenue at 30 June 2020 up 25% and considerable growth in profit margin
          Price Sensitive
        3. Completion of the Closing of the acquisition of Haemonetics Puerto Rico, LLC
          Price Sensitive
        4. 2020 Corporate Events Calendar
          Price Sensitive
        5. GVS Announces the agreement to acquire Puerto Rico-based manufacturing operations of Haemonetics